Skip to content

Released Aug 14, 2017, after the close

10-Q filed Aug 14, 2017, 45 days after period end · 0001390478-17-000059

Q2 2017 · 10-Q
Revenue—
Net Income-$5.91MN/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.22N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$4,911,000N/M
Operating Cash Flowderived-$3,049,000N/M

What the release said

The release

Same quarter

MetricQ2 2017Q2 2016Q2 2013Q2 2012
Revenue——$3.38M$3.38M
Net Income-$5.91M$5.39M$5.39M-$15.66M
EPS Diluted-$0.22$0.58-$0.11-$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR